Abstract:In non-small cell lung cancer (NSCLC) RAS-mutant status is a negative prognostic and predictive factor. The prevalence, clinicopathology and genetic variability of RAS mutation NSCLC patients are unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring RAS mutations. We retrospectively reviewed clinical features from 41 patients with RAS gene mutation NSCLC, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. KRAS gene mutation rate was 8.00% (38/475) in NSCLC, including G12C (9 patients), G12D (8 patients), G12V (7 patients), G12A (2 patients), G12S (2 patients), G13D (2 patients), Q61H (2 patients), G12L (1 patient), G12 (1 patient), G12K (1 patient), G12fs*3 plus G12V (1 patient), G13C plus V14I (1 patient) and K5N (1 patient). Mutation rate of current-smoker was much higher than non-smoker (15.76% and 4.41%, P<0.01), and median overall survival (OS) for these patients was 18.3 months; NRAS gene mutation rate was 0.29% (1/346), G12D, and OS for these patients was 14.2 months; HRAS gene mutation rate was 0.63% (2/315), including H27N and N85I, and median OS for both patients was 19.2 months. Among them, 18 cases of the 41 RAS mutation patients with co-occurring mutations had a median OS of 28.0 months, and median OS of the 23 patients without complex mutations was 21.0 months. No statistically significant difference was found between the two groups (P=0.06). Briefly, patients of KRAS mutations with (n=4) or without (n=34) co-occurring EGFR mutations had a median OS of 40.0 months and 16.3 months respectively (P=0.07); patients with (n=3) or without (n=35) co-occurring TP53 mutations had a median OS of 36.4 months and 18.3 months respectively (P=0.22); patients with (n=3) or without (n=35) co-occurring STK11 mutations had a median OS of not reached so far and 16.3 months respectively (P=0.22); patients with (n=2) or without (n=36) co-occurring KEAP1 mutations had a median OS of 43.6 months and 16.3 months respectively (P=0.06). Mutation rate of KRAS gene in current-smoker NSCLC patients was higher than no-smoker, there is no other significant difference of molecular features in RAS gene mutations in NSCLC. Patients with complex mutations benefited more from therapy than those with single mutations. Immunotherapy may displayed moderate efficacy in patients with TP53 and RAS co-exist mutations.

Four Cases of PTPN11 Associated RASopathies:Analysis of the Correlation Between Gene Mutation and Clinical Phenotype

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

The High Expression of PTPRH is Associated with Poor Prognosis of Human Lung Adenocarcinoma

Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China

[Characteristic Analysis of Adult Acute Myeloid Leukemia Patients with PTPN11 Gene Mutation]

TRPS1 mutation detection in Chinese patients with Tricho-rhino-phalangeal syndrome and identification of four novel mutations

PTPRD/PTPRT Mutation Correlates to Treatment Outcomes of Immunotherapy and Immune Landscape in Pan-Cancers.

Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations

Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.

Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome.

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

PTPN11 Gene Mutations and Its Association with the Risk of Congenital Heart Disease

P53.07 Clinicopathologic Characteristics of Patients with PTPN11 Mutations in East Asian Non-Small Cell Lung Cancer Patients

PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation

Mutation Analysis of the PTPN11 Gene in a Family with LEOPARD Syndrome

P1.02-047 Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations

Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients

RASopathies for Radiologists